Search Results - R. M. Rabinovich
-
1
The Efficacy of Thrombolytic Therapy in Inferior Myocardial Infarction with Damage to the Right Ventricular
Published 2021-05-01Get full textAim. To study the results of thrombolytic therapy and accuracy of electrocardiographic assessment of thrombolysis efficiency in inferior myocardial infarction with and without right ventricular lesion.Material and methods. The118 patients with inferior myocardial infarction were included in this stu...
Article -
2
Cardiac strain in right ventricular myocardial infarction and pulmonary embolism
Published 2020-03-01Get full textAim. To study the prospects of using parameters of right ventricle (RV) longitudinal strain (LS) during systole for the differential diagnosis of RV myocardial infarction (RVMI) and pulmonary embolism (PE).Material and methods. The study included 83 patients who were hospitalized with RVMI or PE in...
Article -
3
THE RESULTS OF USE OF NEW NATIVE THROMBOLYTIC IN CLINICAL PRACTICE
Published 2016-05-01Get full textAim. To assess the efficacy of thrombolytic Fortelyzin in ST elevation myocardial infarction (STEMI) in real clinical practice.Material and methods. Fortelyzin was administered intravenously to 38 patients with STEMI with follow-up assessment of reperfusion success by ECG and angiographic criteria....
Article -
4
Prospects for a pharmacoinvasive strategy in ST-elevation myocardial infarction in the Russian Federation
Published 2025-04-01Get full textIn patients with ST-elevation myocardial infarction, primary percutaneous coronary intervention should be performed within 120 minutes after diagnosis if possible. Timely revascularization helps to preserve left ventricular function, minimizing myocardial damage, which subsequently reduces disabilit...
Article -
5
COMPARATIVE RESULTS OF RECOMBINANT NON-IMMUNOGENIC STAPHYLOKINASE AND TENECTEPLASE USE IN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION IN REAL CLINICAL PRACTICE
Published 2017-09-01Get full textAim. To compare the efficacy and safety of thrombolytic therapy with recombinant non-immunogenic staphylokinase and tenecteplase in ST elevation myocardial infarction (STEMI) in real clinical practice.Material and methods. 84 patients with onset of STEMI symptoms up to 12 hours ago were included int...
Article -
6
Use of glycoprotein IIb/IIIa inhibitors in myocardial infarction in the Russian Federation, according to the Russian Registry of Acute Myocardial Infarction REGION-IM
Published 2024-07-01Get full textAim. To analyze the frequency, indications, and outcomes of using glycoprotein IIb/IIIa inhibitors in patients with acute myocardial infarction (AMI) in Russia based on data from a multicenter registry.Material and methods. This work is part of the REGION-MI (Russian Registry of Acute Myocardial Inf...
Article -
7
Fortelyzin® in comparison with Metalyse® for ST-elevated myocardial infarction: one-year results and clinical outcomes of a multicenter randomized study FRIDOM1
Published 2018-12-01Get full textAim. Evaluate the oneyear results and clinical outcomes of a multicenter randomized clinical trial FRIDOM1.Material and methods. The study FRIDOM1 was conducted in 11 clinical centers of the Russian Federation in the period 20142016. The study included 382 patients with acute STelevated myocardi...
Article -
8
Advanced results of Fortelyzin® use in the FRIDOM1 study and real clinical practice
Published 2022-09-01Get full textAim. To study the effectiveness of Fortelyzin® in subgroups with different body weights in patients with ST-segment elevation acute myocardial infarction (STEMI) in the FRIDOM1 study and real clinical practice.Material and methods. Fortelyzin® was administered in a single-bolus dose of 15 mg over 10...
Article -
9
Non-immunogenic staphylokinase — a thrombolytic agent in the treatment of massive pulmonary embolism: results of the FORPE clinical trial
Published 2024-12-01Get full textAim. To assess the safety and efficacy of a single intravenous bolus of non-immunogenic staphylokinase compared with alteplase in patients with massive pulmonary embolism and hemodynamic instability. Non-immunogenic staphylokinase is a modified recombinant staphylokinase with low immunogenicity, hig...
Article